Status:
UNKNOWN
Sirolimus in the Treatment for Infantile Hepatic Hemangioendothelioma(IEEH)
Lead Sponsor:
Shanghai Children's Medical Center
Conditions:
Hemangioendothelioma of Liver
Eligibility:
All Genders
1-36 years
Phase:
PHASE4
Brief Summary
Infantile hepatic hemangioendothelioma (IHHE) is an infantile hemangioma involving the liver.Since 2008, propranolol has been used for the treatment of hemangioma, and some researchers have also start...
Detailed Description
According to the World Health Organization(WHO) classification of digestive system tumors in the fourth edition in 2010, infantile hepatic hemangioendothelioma (IHHE) is an infantile hemangioma involv...
Eligibility Criteria
Inclusion
- Confirmed as IHHE
- Age between 1 month and 36 months
- Receiving propranolol for 3 months but the tumor size shrinks \<30%
- With written informed consent
Exclusion
- Confirmed as hepatoblastoma
- Have accepted surgical resection
- Clinical data missing
- Patients with Kasabach-Merritt phenomenon
- Receiving propranolol for 3 months and the tumor size shrinks \>30%
Key Trial Info
Start Date :
July 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2025
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT04406870
Start Date
July 1 2020
End Date
June 30 2025
Last Update
May 29 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Children's Medical Center Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China, 200127